Palvella Therapeutics Inc. (PVLA)
NASDAQ: PVLAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
PVLA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.88B
- EPS (TTM)
- -$4.85
- Dividend yield
- None
- 52-week range
- 65.93 – 161.38
- Day range
- 125.00 – 131.35
- Volume / Avg
- 148.94K / 211.90K
- Beta
- —
- Shares outstanding
- 14.41M
52-week range
PVLA stock today
Palvella Therapeutics (PVLA) closed at $130.59 on Oct 7, up 2.02% (+$2.59), versus the S&P 500's 0.22% decline. Shares are 19.1% below their 52-week high of $161.38, set on Jun 30, 2026 and 98.1% above the 52-week low of $65.93, in the middle of the past year's range. PVLA is up 24.8% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 84.7%.
Palvella Therapeutics has posted a net loss over the last twelve months (EPS of -$4.85), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Palvella Therapeutics
Company profilePalvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Wesley H. Kaupinen
- Headquarters
- Wayne, PA
- Employees
- 29
- Website
- palvellatx.com
Analyst forecast
ForecastConsensus (15 analysts)
none
Avg. price target
$230.53+76.53%
- Strong buy 0
- Buy 15
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Palvella Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| XERSXeris Biopharma Holdings Inc. | 10.11 | +0.40% | $1.84B | vs PVLA |
| SRPTSarepta Therapeutics Inc. | 17.50 | +1.10% | $1.85B | vs PVLA |
| ADRXADARx Pharmaceuticals Inc. | 17.33 | -6.73% | $1.85B | vs PVLA |
| ZBIOZenas BioPharma Inc. | 28.18 | +4.60% | $1.84B | vs PVLA |
| TRVITrevi Therapeutics Inc. | 13.14 | -0.30% | $1.87B | vs PVLA |
| XNCRXencor Inc. | 24.26 | -0.41% | $1.80B | vs PVLA |
| BHVNBiohaven Ltd. | 11.88 | -1.66% | $1.79B | vs PVLA |
| AGIOAgios Pharmaceuticals Inc. | 31.79 | +0.22% | $1.90B | vs PVLA |
Indexes, lists and sector
Palvella Therapeutics stock FAQ
What is Palvella Therapeutics's stock price today?
PVLA last traded at $130.59 as of Oct 7, 4:00 PM EDT, up 2.02% on the day. Prices are delayed at least 15 minutes.
Does Palvella Therapeutics pay a dividend?
No. Palvella Therapeutics does not currently pay a regular cash dividend.
Who is Palvella Therapeutics's CEO?
Mr. Wesley H. Kaupinen is the chief executive officer of Palvella Therapeutics Inc., which has about 29 employees.
Has PVLA ever split its stock?
Yes. The most recent PVLA stock split was a 1-for-80 split on Apr 23, 2024.
What is the PVLA 52-week high?
The 52-week high for PVLA is $161.38 and the 52-week low is $65.93. The stock is currently 19.1% below its high.